Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337873 | 0.86 | MAPT (0.79) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL3339779 | 0.85 | LMNA (0.79) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL3342093 | 0.84 | MAPT (0.72) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL3335920 | 0.82 | MAPT (0.71) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL3337680 | 0.81 | CA12 (0.62) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL3337838 | 0.80 | LMNA (0.56) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL3337733 | 0.79 | RAB9A (0.77) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL31006484 | 0.78 | ALDH1A1 (0.75) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL28871814 | 0.78 | ALDH1A1 (0.75) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3338316 | 0.78 | MAPT (0.74) | MAPTMEN1KMT2ARAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410152-B2 | Thiazolhydrazides for treatment of neurodegenerative diseases | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2013-04-02 | — | — | US | claimed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | claimed |
| US-8410152-B2 | Thiazolhydrazides for treatment of neurodegenerative diseases | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | MAPT 2/4885MEN1 1886/4885KMT2A 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.